sanofi9d
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the ...
sanofi7d
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of Directors Paris, . Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, ...
sanofi9d
Press Release: Availability of the Q4 2024 Aide-mémoire
Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website: ...
sanofi13d
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...
sanofi9d
E. coli sepsis
Sepsis is a life-threatening condition that happens when the body’s immune system has an extreme response to an infection.
sanofi18y
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
First non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infections Two phase 1/2 clinical studies are ongoing to evaluate the safety ...